DUBLIN--(BUSINESS WIRE)--The "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 10, 8, 15, 6 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.
Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Attention Deficit Hyperactivity Disorder (ADHD) - Overview
- Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development
- 4P-Pharma SAS
- Aevi Genomic Medicine Inc
- Alcobra Ltd
- Amarantus Bioscience Holdings Inc
- APeT Holding BV
- BCWorld Pharm Co Ltd
- BioHealthonomics Inc
- Cingulate Therapeutics LLC
- Collegium Pharmaceutical Inc
- Curemark LLC
- DURECT Corp
- Eli Lilly and Company
- H. Lundbeck A/S
- Heptares Therapeutics Ltd
- Highland Therapeutics Inc
- KemPharm Inc
- Luc Therapeutics Inc
- Merck & Co Inc
- Neos Therapeutics Inc
- NeuroDerm Ltd
- Novartis AG
- Noven Pharmaceuticals Inc
- Otsuka Pharmaceutical Co Ltd
- P2D Bioscience
- Reviva Pharmaceuticals Inc
- Shire Plc
- SK Biopharmaceuticals Co Ltd
- Sunovion Pharmaceuticals Inc
- Supernus Pharmaceuticals Inc
- Taisho Pharmaceutical Holdings Co Ltd
- Tris Pharma Inc
For more information about this report visit https://www.researchandmarkets.com/research/jvcsw6/attention_deficit
